Prostate cancer and PARP inhibitors: progress and challenges.
DNA repair
Homologous recombination repair
PARP inhibitors
Prostate cancers
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
29 03 2021
29 03 2021
Historique:
received:
14
12
2020
accepted:
10
03
2021
entrez:
30
3
2021
pubmed:
31
3
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic alterations of DNA-damage response pathway genes are found in a substantial number of patients with advanced prostate cancers, mainly of poor prognosis. Such alterations induce a dependency for single strand break reparation through the poly(adenosine diphosphate-ribose) polymerase (PARP) system, providing the rationale to develop PARP inhibitors. In solid tumors, the first demonstration of an improvement in overall survival was provided by olaparib in patients with mCRPC harboring homologous recombination repair deficiencies. Although this represents a major milestone, a number of issues relating to PARP inhibitors remain. This timely review synthesizes and discusses the rationale and development of PARP inhibitors, biomarker-based approaches associated and the future challenges related to their prescription as well as patient pathways.
Identifiants
pubmed: 33781305
doi: 10.1186/s13045-021-01061-x
pii: 10.1186/s13045-021-01061-x
pmc: PMC8008655
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Références
Mol Cancer Ther. 2014 Feb;13(2):433-43
pubmed: 24356813
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Invest New Drugs. 2014 Oct;32(5):904-12
pubmed: 24764124
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Nat Commun. 2017 Oct 16;8(1):859
pubmed: 29038466
Am J Kidney Dis. 2020 Dec;76(6):898-900
pubmed: 32679152
Br J Cancer. 2010 Sep 7;103(6):918-24
pubmed: 20736950
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
J Clin Oncol. 2018 Apr 1;36(10):991-999
pubmed: 29261439
Xenobiotica. 2017 Oct;47(10):903-915
pubmed: 27684210
Eur Urol. 2018 Aug;74(2):218-225
pubmed: 29439820
Nat Commun. 2017 Aug 29;8(1):374
pubmed: 28851861
Eur Urol. 2017 May;71(5):740-747
pubmed: 27989354
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Eur Urol. 2020 Dec;78(6):822-830
pubmed: 32811715
JAMA Oncol. 2019 Apr 01;5(4):523-528
pubmed: 30730552
J Biol Chem. 1982 Jan 25;257(2):607-9
pubmed: 6274856
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Mol Cell Biol. 2004 Jan;24(2):708-18
pubmed: 14701743
Urol Oncol. 2018 Nov;36(11):500.e1-500.e9
pubmed: 30201382
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Nat Commun. 2017 Aug 22;8(1):319
pubmed: 28831036
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
JCO Precis Oncol. 2021 Jul 22;5:
pubmed: 34778690
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
Oncotarget. 2015 Jan 1;6(1):234-42
pubmed: 25428917
J Cell Biol. 2012 Oct 15;199(2):235-49
pubmed: 23045548
Am J Pathol. 2018 Jun;188(6):1478-1485
pubmed: 29577933
Clin Cancer Res. 2021 Jan 15;27(2):566-574
pubmed: 32988971
J Immunother Cancer. 2018 Dec 4;6(1):141
pubmed: 30514390
Xenobiotica. 2020 Sep;50(9):1032-1042
pubmed: 32129697
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Cell Rep. 2020 Oct 6;33(1):108221
pubmed: 33027668
Nat Struct Mol Biol. 2010 Oct;17(10):1260-2
pubmed: 20729859
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Cancer Res. 1991 Jun 15;51(12):3075-9
pubmed: 2039987
J Med Chem. 2017 Feb 23;60(4):1262-1271
pubmed: 28001384
Eur Urol. 2019 Dec;76(6):831-842
pubmed: 31537406
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Clin Cancer Res. 2011 Feb 1;17(3):401-5
pubmed: 21088254
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Mol Cell Biol. 2003 Jun;23(11):3974-81
pubmed: 12748298
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
JCO Precis Oncol. 2020;4:382-392
pubmed: 32671317
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
J Clin Invest. 2020 Apr 1;130(4):1743-1751
pubmed: 31874108
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
pubmed: 18971340
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5172-7
pubmed: 9560248
Prostate. 2018 Jun;78(8):607-615
pubmed: 29520813
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Nat Commun. 2020 Jul 24;11(1):3726
pubmed: 32709856
Acta Pharmacol Sin. 2015 Jan;36(1):3-23
pubmed: 24909511
Genes Dev. 1997 Sep 15;11(18):2347-58
pubmed: 9308963
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Hum Mol Genet. 2001 Oct 1;10(20):2253-9
pubmed: 11673408
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Cancer Discov. 2017 Sep;7(9):999-1005
pubmed: 28450426
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
BMC Genomics. 2005 Oct 04;6:139
pubmed: 16202152
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
J Pharmacol Exp Ther. 2014 Jun;349(3):408-16
pubmed: 24650937
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Sci Signal. 2020 Aug 18;13(645):
pubmed: 32817374
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Eur Urol. 2019 Apr;75(4):667-675
pubmed: 30638634
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Mol Cell. 2012 Apr 27;46(2):125-35
pubmed: 22445484